Skip to search formSkip to main contentSkip to account menu

MST 16

Known as: MST-16 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sobuzoxane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Anticancer activities and mechanisms of bisdioxopiperazine compounds probimane and MST-16.
Bisdioxopiperazine compounds, including ICRF-154 and razoxane (ICRF-159, Raz), are anticancer agents developed in the UK… 
2008
2008
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models
SummaryWe studied the antitumor activity of newly synthesized bis(1-acyloxymethyl) derivatives of 4,4′-(1,2-ethanediyl)bis(2,6… 
2001
2001
Long-Term Administration of Oral Low-Dose Topoisomerase II Inhibitors, MST-16 and VP-16, for Refractory or Relapsed Non-Hodgkin’s Lymphoma
It is known that the topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of… 
1999
1999
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
MST-16 [4,4-1,2-(ethanediyl)bis(1-isobutoxycarbonyl-oxy-methyl-2,6-pipera zinedione)], recently approved as an oral anticancer… 
1998
1998
MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines
MST-16, a derivative of bis(2,6-dioxopiperazine), is a newly developed anticancer agent that is potentially effective in… 
Highly Cited
1993
Highly Cited
1993
Treatment of adult T‐cell leukemia/lymphoma with MST‐16, a new oral antitumor drug and a derivative of bis(2,6‐dioxopiperazine)
Background. MST‐16, a new orally administered bis(2,6‐dioxopiperazine) analogue and an inhibitor of topoisomerase II, was given… 
1992
1992
Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.
Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients… 
1992
1992
Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
BACKGROUND Although razoxane (ICRF-159), a derivative of bis(2,6-dioxopiperazine), has shown significant antitumor activity in… 
1992
1992
Arrest in late G2 or prophase of cell cycle induced by 4,4‐(l,2‐ethanediyl) bis (1‐isobutoxycarbonyloxymethyl 2, 6‐piperazinedione) (MST‐16) in cultured l1210 cells
The effects of MST‐16, a new antitumor agent derived from bis (2, 6‐dioxopiperazine), on cell growth, cell‐cycle progression and… 
1990
1990
[Phase I study of MST-16].
Phase I study with a new oral anticancer agents. MST-16 (Sobuzoxane), was conducted by 3 administration schedules: single, 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)